Kharlamova Olga Sergeevna

@iimed.ru

The Scientific Research Institute of Therapy and Preventive Medicine is a branch of the Federal State Budgetary Scientific Institution "Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences"



           

https://researchid.co/kharlamovaos

Нead of the therapeutic department City Clinical Hospital #25 2014
Therapist City Clinical Hospital #25 2012
Doctor Resident FGBU Research Institute of Clinical and Experimental Lymphology SO RAN 2010

EDUCATION

Professional Retraining on therapy
Certificate # 19992 080000001608
Professional Retraining on therapy
Certificate # 0154180640839
Professional Retraining on therapy
Certificate # Б0000004
MD
Diploma # ВСГ 5474781

5

Scopus Publications

Scopus Publications

  • Surfactant Proteins SP-A and SP-D and Conventional Risk Factors for Chronic Noncommunicable Human Diseases
    K. Yu. Nikolaev, O. S. Kharlamova, I. A. Kosarev, N. F. Dadashova, and Y. K. Lapitskay
    Pleiades Publishing Ltd

  • SP-A and SP-D surfactant proteins and conventional risk factors for chronic non-infectious human diseases
    K. Yu. Nikolaev, O. S. Kharlamova, I. A. Kosarev, N. F. Dadashova, and Ya. K. Lapitskaya
    Institute of Cytology and Genetics, SB RAS
    Surfactant proteins SP-A and SP-D, which belong to the family of collagen-containing type C lectins, are used as diagnostic and prognostic markers for many acute and chronic respiratory diseases. The aim of the study is to assess the impact of conventional risk factors for chronic non-infectious diseases on SP-A and SP-D protein levels by means of systemic and structural analysis on the basis of relevant publications from international databases and official WHO reports. This analytical review concludes that widespread expression of SP-A and SP-D is documented in numerous studies, and, although the lungs remain the main site of synthesis of surfactant proteins, one can expect its significant impact on the immune and inflammatory response in many organs and tissues. The authors note that there are several known extrapulmonary effects of these proteins. However, many mechanisms of additional cellular effects of SP-A and SP-D outside the bronchopulmonary system still remain unstudied, which indicates the prospects for further research in this area.

  • The role of surfactant proteins SP-A and SP-D in viral infection: a focus on COVID-19
    O. S. Kharlamovа, K. Yu. Nikolaev, and Yu. I. Ragino
    Siberian State Medical University
    An immune response to invasion of viral pathogens is an integral part of maintaining the physiological functioning of the bronchopulmonary system and effective gas exchange. Collagen-containing C-type lectins (lung collectins) are some of the key proteins in the identification of viral particles. They have image-recognizing receptors that identify pathogen-associated molecular patterns, particularly viral glycoproteins. The surfactant proteins SP-A and SP-D, which are composed of trimerized units, belong to pulmonary collectins and oligomerize into higher-order structures. These proteins play an essential role in recognition and elimination of microbial pathogens (viruses, bacteria, fungi, parasites, nanoparticles, allergens) through a variety of mechanisms. Taking into account the burden of the novel coronavirus infection caused by the SARS-CoV-2 virus, it is important to consider the role of the surfactant proteins SP-A and SP-D in the pathogenesis of the immune response to viral invasion. Currently, there are data on the direct relationship between surfactant proteins and viruses belonging to the Coronaviridae family. The SP-A and SP-D proteins modulate inflammatory responses and cytokine synthesis, but prevent an excessive inflammatory response (cytokine storm). There is also an assumption that SARSCoV-2 directly suppresses and alters the production of surfactant proteins. Thus, the key pathogenetic role of the surfactant proteins SP-A and SP-D in the response to the viral pathogen SARS-CoV-2 is evident. Today, this is a promising area of translational medicine, which will contribute to a profound understanding of the pathogenesis of coronavirus infection for assessing the diagnostic and prognostic potentials of the surfactant proteins SP-A and SP-D in COVID-19. Additionally, it will help evaluate the therapeutic potential of recombinant fragments of human SP-A and SP-D. 

  • Association of SP-A and SP-D surfactant proteins with the severity of community-acquired pneumonia
    O. S. Kharlamova, K. Y. Nikolayev, Y. I. Ragino, and M. I. Voyevoda
    The Scientific and Practical Society of Emergency Medicine Physicians
    Relevance. In current clinical practice, there is a need for research to find new diagnostic tests for the purpose of determining the patients with the highest risk of death from pneumonia. Surfactant proteins SP-A and SP-D play a key role in the pathogenesis of the response to microbial invasion of lung tissue, which participate in a cascade of reactions of both innate and adaptive immunity, and therefore proteins SP-A and SP-D may be considered as markers of the severity of community-acquired pneumonia (CAP).Aim of study. To evaluate the associations of surfactant proteins SP-A and SP-D in blood plasma with the severity of CAP.Material and methods. The study included 247 patients admitted to the therapeutic department. The group of patients with CAP (n=188) was divided into groups of severe (n=103) and non-severe (n=85) pneumonia. The comparison group (n=59) consisted of patients without acute and chronic diseases of the bronchi and lungs. The mean age (years, Me, 25th; 75th percentile) of patients was 55 (47; 68), 55 (47; 70), and 61 (37; 63) years, respectively. All patients underwent clinical, functional, diagnostic and laboratory studies (including determination of the content of SP-A and SP-D proteins by enzyme immunoassay).Results. In the group of patients with severe pneumonia unlike mild pneumonia, and group of comparison higher levels of proteins SP-A and SP-D were observed. Correlation analysis described below revealed statistically significant connection: protein SP-D — direct relation with leukocyte levels (r=0.320, p<0.0001), erythrocyte sedimentation rate (r=0.331, p<0.0001), inverse relation with blood oxygen saturation (r=-0.407, p<0.0001), for SP-A protein — direct relation with body temperature (r=0.355, p<0.0001), erythrocyte sedimentation rate (r=0.369, p<0.0001) in the blood C-reactive protein (r=0.446, p<0.0001), SP-D (r=0.357, p<0.0001), and also relation with the duration of clinical symptoms (r=0.528, p<0.0001) and blood oxygen saturation (r=-0.401, p<0.0001). When conducting ROCanalysis for the surfactant protein SP-A, the area under the ROC- curve was 0.70, the optimal sensitivity for severe pneumonia was 68%, the specificity was 69% at the SP-A level in blood plasma equal to 42.9 ng/ml. When performing ROC analysis for the surfactant protein SP-D, the area under the ROC curve was 0.64 for severe pneumonia, the optimal sensitivity was 62%, and the specificity was 62% at the SP-D content in blood plasma equal to 319.2 ng/ml.Conclusion. According to the results of this study, the SP-A and SP-D proteins are associated with clinical and laboratory signs that reflect the severity of CAP. Thus, SP-A and SP-D are new laboratory markers of CAP severity.